+1 (704) 266-3234

Global Biosimilar Monoclonal Antibodies Market Growth 2021-2026

Published on: Jan 2021 | From USD $2900 | Published By: LP INFORMATION INC | Number Of Pages: 130

According to this latest study, the 2020 growth of Biosimilar Monoclonal Antibodies will have significant change from previous year. By the most conservative estimates of global Biosimilar Monoclonal Antibodies market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2020, from US$ 4474.8 million in 2019. Over the next five years the Biosimilar Monoclonal Antibodies market will register a 28.7% CAGR in terms of revenue, the global market size will reach US$ 12290 million by 2025.

This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar Monoclonal Antibodies market by product type, application, key manufacturers and key regions and countries.

Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.
Infliximab
Rituximab
Trastuzumab
Adalimumab
Other

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.
Oncology
Autoimmune Disease
Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.
Celltrion
Pfizer (Hospira)
3SBIO
Novartis (Sandoz)
Dr Reddy’s
Celgen Biopharma
Cadila Healthcare
Hisun Pharma
Torrent Pharmaceuticals

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 Executive Summary
2.1 World Market Overview
2.1.1 Global Biosimilar Monoclonal Antibodies Consumption 2016-2026
2.1.2 Biosimilar Monoclonal Antibodies Consumption CAGR by Region
2.2 Biosimilar Monoclonal Antibodies Segment by Type
2.2.1 Infliximab
2.2.2 Rituximab
2.2.3 Trastuzumab
2.2.4 Adalimumab
2.2.5 Other
2.3 Biosimilar Monoclonal Antibodies Sales by Type
2.3.1 Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2016-2021)
2.3.2 Global Biosimilar Monoclonal Antibodies Revenue and Market Share by Type (2016-2021)
2.3.3 Global Biosimilar Monoclonal Antibodies Sale Price by Type (2016-2021)
2.4 Biosimilar Monoclonal Antibodies Segment by Application
2.4.1 Oncology
2.4.2 Autoimmune Disease
2.4.3 Other
2.5 Biosimilar Monoclonal Antibodies Sales by Application
2.5.1 Global Biosimilar Monoclonal Antibodies Sale Market Share by Application (2016-2021)
2.5.2 Global Biosimilar Monoclonal Antibodies Revenue and Market Share by Application (2016-2021)
2.5.3 Global Biosimilar Monoclonal Antibodies Sale Price by Application (2016-2021)

3 Global Biosimilar Monoclonal Antibodies by Company
3.1 Global Biosimilar Monoclonal Antibodies Sales Market Share by Company
3.1.1 Global Biosimilar Monoclonal Antibodies Sales by Company (2019-2021)
3.1.2 Global Biosimilar Monoclonal Antibodies Sales Market Share by Company (2019-2021)
3.2 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Company
3.2.1 Global Biosimilar Monoclonal Antibodies Revenue by Company (2019-2021)
3.2.2 Global Biosimilar Monoclonal Antibodies Revenue Market Share by Company (2019-2021)
3.3 Global Biosimilar Monoclonal Antibodies Sale Price by Company
3.4 Global Manufacturers Biosimilar Monoclonal Antibodies Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Biosimilar Monoclonal Antibodies Product Location Distribution
3.4.2 Players Biosimilar Monoclonal Antibodies Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion

4 Biosimilar Monoclonal Antibodies by Region
4.1 Global Biosimilar Monoclonal Antibodies by Region
4.1.1 Global Biosimilar Monoclonal Antibodies Sales by Region
4.1.2 Global Biosimilar Monoclonal Antibodies Revenue by Region
4.2 Americas Biosimilar Monoclonal Antibodies Sales Growth
4.3 APAC Biosimilar Monoclonal Antibodies Sales Growth
4.4 Europe Biosimilar Monoclonal Antibodies Sales Growth
4.5 Middle East & Africa Biosimilar Monoclonal Antibodies Sales Growth

5 Americas
5.1 Americas Biosimilar Monoclonal Antibodies Sales by Country
5.1.1 Americas Biosimilar Monoclonal Antibodies Sales by Country (2016-2021)
5.1.2 Americas Biosimilar Monoclonal Antibodies Revenue by Country (2016-2021)
5.2 Americas Biosimilar Monoclonal Antibodies Sales by Type
5.3 Americas Biosimilar Monoclonal Antibodies Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC
6.1 APAC Biosimilar Monoclonal Antibodies Sales by Region
6.1.1 APAC Biosimilar Monoclonal Antibodies Sales by Region (2016-2021)
6.1.2 APAC Biosimilar Monoclonal Antibodies Revenue by Region (2016-2021)
6.2 APAC Biosimilar Monoclonal Antibodies Sales by Type
6.3 APAC Biosimilar Monoclonal Antibodies Sales by Application
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 Europe
7.1 Europe Biosimilar Monoclonal Antibodies by Country
7.1.1 Europe Biosimilar Monoclonal Antibodies Sales by Country (2016-2021)
7.1.2 Europe Biosimilar Monoclonal Antibodies Revenue by Country (2016-2021)
7.2 Europe Biosimilar Monoclonal Antibodies Sales by Type
7.3 Europe Biosimilar Monoclonal Antibodies Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 Middle East & Africa
8.1 Middle East & Africa Biosimilar Monoclonal Antibodies by Country
8.1.1 Middle East & Africa Biosimilar Monoclonal Antibodies Sales by Country (2016-2021)
8.1.2 Middle East & Africa Biosimilar Monoclonal Antibodies Revenue by Country (2016-2021)
8.2 Middle East & Africa Biosimilar Monoclonal Antibodies Sales by Type
8.3 Middle East & Africa Biosimilar Monoclonal Antibodies Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Country

9 Market Drivers, Challenges and Trends
9.1 Market Drivers and Impact
9.1.1 Growing Demand from Key Regions
9.1.2 Growing Demand from Key Applications and Potential Industries
9.2 Market Challenges and Impact
9.3 Market Trends

10 Marketing, Distributors and Customer
10.1 Sales Channel
10.1.1 Direct Channels
10.1.2 Indirect Channels
10.2 Biosimilar Monoclonal Antibodies Distributors
10.3 Biosimilar Monoclonal Antibodies Customer

11 Global Biosimilar Monoclonal Antibodies Market Forecast
11.1 Global Biosimilar Monoclonal Antibodies Forecast by Region
11.1.1 Global Biosimilar Monoclonal Antibodies Forecast by Regions (2021-2026)
11.2.2 Global Biosimilar Monoclonal Antibodies Revenue Forecast by Regions (2021-2026)
11.2 Americas Forecast by Countries
11.3 APAC Forecast by Region
11.4 Europe Forecast by Countries
11.5 Middle East & Africa Forecast by Countries
11.6 Global Biosimilar Monoclonal Antibodies Forecast by Type
11.7 Global Biosimilar Monoclonal Antibodies Forecast by Application

12 Key Players Analysis
12.1 Celltrion
12.1.1 Celltrion Celltrion Company Information
12.1.2 Celltrion Biosimilar Monoclonal Antibodies Product Offered
12.1.3 Celltrion Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2019-2021)
12.1.4 Celltrion Main Business Overview
12.1.5 Celltrion Latest Developments
12.2 Pfizer (Hospira)
12.2.1 Pfizer (Hospira) Company Information
12.2.2 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Offered
12.2.3 Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2019-2021)
12.2.4 Pfizer (Hospira) Main Business Overview
12.2.5 Pfizer (Hospira) Latest Developments
12.3 3SBIO
12.3.1 3SBIO Company Information
12.3.2 3SBIO Biosimilar Monoclonal Antibodies Product Offered
12.3.3 3SBIO Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2019-2021)
12.3.4 3SBIO Main Business Overview
12.3.5 3SBIO Latest Developments
12.4 Novartis (Sandoz)
12.4.1 Novartis (Sandoz) Company Information
12.4.2 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Offered
12.4.3 Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2019-2021)
12.4.4 Novartis (Sandoz) Main Business Overview
12.4.5 Novartis (Sandoz) Latest Developments
12.5 Dr ReddyÂ’s
12.5.1 Dr ReddyÂ’s Company Information
12.5.2 Dr ReddyÂ’s Biosimilar Monoclonal Antibodies Product Offered
12.5.3 Dr ReddyÂ’s Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2019-2021)
12.5.4 Dr ReddyÂ’s Main Business Overview
12.5.5 Dr ReddyÂ’s Latest Developments
12.6 Celgen Biopharma
12.6.1 Celgen Biopharma Company Information
12.6.2 Celgen Biopharma Biosimilar Monoclonal Antibodies Product Offered
12.6.3 Celgen Biopharma Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2019-2021)
12.6.4 Celgen Biopharma Main Business Overview
12.6.5 Celgen Biopharma Latest Developments
12.7 Cadila Healthcare
12.7.1 Cadila Healthcare Company Information
12.7.2 Cadila Healthcare Biosimilar Monoclonal Antibodies Product Offered
12.7.3 Cadila Healthcare Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2019-2021)
12.7.4 Cadila Healthcare Main Business Overview
12.7.5 Cadila Healthcare Latest Developments
12.8 Hisun Pharma
12.8.1 Hisun Pharma Company Information
12.8.2 Hisun Pharma Biosimilar Monoclonal Antibodies Product Offered
12.8.3 Hisun Pharma Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2019-2021)
12.8.4 Hisun Pharma Main Business Overview
12.8.5 Hisun Pharma Latest Developments
12.9 Torrent Pharmaceuticals
12.9.1 Torrent Pharmaceuticals Company Information
12.9.2 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Offered
12.9.3 Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales, Revenue, Price and Gross Margin (2019-2021)
12.9.4 Torrent Pharmaceuticals Main Business Overview
12.9.5 Torrent Pharmaceuticals Latest Developments

13 Research Findings and Conclusion

List of Tables
Table 1. Biosimilar Monoclonal Antibodies Consumption CAGR by Region (2020-2026) & ($ Millions)
Table 2. Major Players of Infliximab
Table 3. Major Players of Rituximab
Table 4. Major Players of Trastuzumab
Table 5. Major Players of Adalimumab
Table 6. Major Players of Other
Table 7. Global Biosimilar Monoclonal Antibodies Sales by Type (2016-2021) & (K Units)
Table 8. Global Biosimilar Monoclonal Antibodies Sales Market Share by Type (2016-2021)
Table 9. Global Biosimilar Monoclonal Antibodies Revenue by Type (2016-2021) & ($ million)
Table 10. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2016-2021)
Table 11. Global Biosimilar Monoclonal Antibodies Sale Price by Type (2016-2021)
Table 12. Global Biosimilar Monoclonal Antibodies Sales by Application (2016-2021) & (K Units)
Table 13. Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2016-2021)
Table 14. Global Biosimilar Monoclonal Antibodies Value by Application (2016-2021)
Table 15. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application (2016-2021)
Table 16. Global Biosimilar Monoclonal Antibodies Sale Price by Application (2016-2021)
Table 17. Global Biosimilar Monoclonal Antibodies Sales by Company (2019-2021) & (K Units)
Table 18. Global Biosimilar Monoclonal Antibodies Sales Market Share by Company (2019-2021)
Table 19. Global Biosimilar Monoclonal Antibodies Revenue by Company (2019-2021) ($ Millions)
Table 20. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Company (2019-2021)
Table 21. Global Biosimilar Monoclonal Antibodies Sale Price by Company (2019-2021)
Table 22. Key Manufacturers Biosimilar Monoclonal Antibodies Producing Area Distribution and Sales Area
Table 23. Players Biosimilar Monoclonal Antibodies Products Offered
Table 24. Biosimilar Monoclonal Antibodies Concentration Ratio (CR3, CR5 and CR10) & (2019-2021)
Table 25. New Products and Potential Entrants
Table 26. Mergers & Acquisitions, Expansion
Table 27. Global Biosimilar Monoclonal Antibodies Sales by Region (2016-2021) (K Units)
Table 28. Global Biosimilar Monoclonal Antibodies Sales Market Share by Region (2016-2021)
Table 29. Global Biosimilar Monoclonal Antibodies Revenue by Region (2016-2021) & ($ Millions)
Table 30. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2016-2021)
Table 31. Americas Biosimilar Monoclonal Antibodies Sales by Country (2016-2021) & (K Units)
Table 32. Americas Biosimilar Monoclonal Antibodies Sales Market Share by Country (2016-2021)
Table 33. Americas Biosimilar Monoclonal Antibodies Revenue by Country (2016-2021) & ($ Millions)
Table 34. Americas Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2016-2021)
Table 35. Americas Biosimilar Monoclonal Antibodies Sales by Type (2016-2021) & (K Units)
Table 36. Americas Biosimilar Monoclonal Antibodies Sales Market Share by Type (2016-2021)
Table 37. Americas Biosimilar Monoclonal Antibodies Sales by Application (2016-2021) & (K Units)
Table 38. Americas Biosimilar Monoclonal Antibodies Sales Market Share by Application (2016-2021)
Table 39. APAC Biosimilar Monoclonal Antibodies Sales by Region (2016-2021) & (K Units)
Table 40. APAC Biosimilar Monoclonal Antibodies Sales Market Share by Region (2016-2021)
Table 41. APAC Biosimilar Monoclonal Antibodies Revenue by Region (2016-2021) & ($ Millions)
Table 42. APAC Biosimilar Monoclonal Antibodies Revenue Market Share by Region (2016-2021)
Table 43. APAC Biosimilar Monoclonal Antibodies Sales by Type (2016-2021) & (K Units)
Table 44. APAC Biosimilar Monoclonal Antibodies Sales Market Share by Type (2016-2021)
Table 45. APAC Biosimilar Monoclonal Antibodies Sales by Application (2016-2021) & (K Units)
Table 46. APAC Biosimilar Monoclonal Antibodies Sales Market Share by Application (2016-2021)
Table 47. Europe Biosimilar Monoclonal Antibodies Sales by Country (2016-2021) & (K Units)
Table 48. Europe Biosimilar Monoclonal Antibodies Sales Market Share by Country (2016-2021)
Table 49. Europe Biosimilar Monoclonal Antibodies Revenue by Country (2016-2021) & ($ Millions)
Table 50. Europe Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2016-2021)
Table 51. Europe Biosimilar Monoclonal Antibodies Sales by Type (2016-2021) & (K Units)
Table 52. Europe Biosimilar Monoclonal Antibodies Sales Market Share by Type (2016-2021)
Table 53. Europe Biosimilar Monoclonal Antibodies Sales by Application (2016-2021) & (K Units)
Table 54. Europe Biosimilar Monoclonal Antibodies Sales Market Share by Application (2016-2021)
Table 55. Middle East & Africa Biosimilar Monoclonal Antibodies Sales by Country (2016-2021) & (K Units)
Table 56. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Market Share by Country (2016-2021)
Table 57. Middle East & Africa Biosimilar Monoclonal Antibodies Revenue by Country (2016-2021) & ($ Millions)
Table 58. Middle East & Africa Biosimilar Monoclonal Antibodies Revenue Market Share by Country (2016-2021)
Table 59. Middle East & Africa Biosimilar Monoclonal Antibodies Sales by Type (2016-2021) & (K Units)
Table 60. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Market Share by Type (2016-2021)
Table 61. Middle East & Africa Biosimilar Monoclonal Antibodies Sales by Application (2016-2021) & (K Units)
Table 62. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Market Share by Application (2016-2021)
Table 63. Global Biosimilar Monoclonal Antibodies Sales Forecast by Type (2021-2026) & (K Units)
Table 64. Global Biosimilar Monoclonal Antibodies Sales Market Share Forecast by Type (2021-2026)
Table 65. Global Biosimilar Monoclonal Antibodies Revenue Forecast by Type (2021-2026) & ($ Millions)
Table 66. Global Biosimilar Monoclonal Antibodies Revenue Market Share Forecast by Type (2021-2026)
Table 67. Global Biosimilar Monoclonal Antibodies Sales Forecast by Application (2021-2026) & (K Units)
Table 68. Global Biosimilar Monoclonal Antibodies Sales Market Share Forecast by Application (2021-2026)
Table 69. Global Biosimilar Monoclonal Antibodies Revenue Forecast by Application (2021-2026) & ($ Millions)
Table 70. Global Biosimilar Monoclonal Antibodies Revenue Market Share Forecast by Application (2021-2026)
Table 71. Celltrion Basic Information, Biosimilar Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 72. Celltrion Biosimilar Monoclonal Antibodies Product Offered
Table 73. Celltrion Biosimilar Monoclonal Antibodies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 74. Celltrion Main Business
Table 75. Celltrion Latest Developments
Table 76. Pfizer (Hospira) Basic Information, Biosimilar Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 77. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Product Offered
Table 78. Pfizer (Hospira) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 79. Pfizer (Hospira) Main Business
Table 80. Pfizer (Hospira) Latest Developments
Table 81. 3SBIO Basic Information, Biosimilar Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 82. 3SBIO Biosimilar Monoclonal Antibodies Product Offered
Table 83. 3SBIO Biosimilar Monoclonal Antibodies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 84. 3SBIO Main Business
Table 85. 3SBIO Latest Developments
Table 86. Novartis (Sandoz) Basic Information, Biosimilar Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 87. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Product Offered
Table 88. Novartis (Sandoz) Biosimilar Monoclonal Antibodies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 89. Novartis (Sandoz) Main Business
Table 90. Novartis (Sandoz) Latest Developments
Table 91. Dr Reddy’s Basic Information, Biosimilar Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 92. Dr Reddy’s Biosimilar Monoclonal Antibodies Product Offered
Table 93. Dr Reddy’s Biosimilar Monoclonal Antibodies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 94. Dr Reddy’s Main Business
Table 95. Dr Reddy’s Latest Developments
Table 96. Celgen Biopharma Basic Information, Biosimilar Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 97. Celgen Biopharma Biosimilar Monoclonal Antibodies Product Offered
Table 98. Celgen Biopharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 99. Celgen Biopharma Main Business
Table 100. Celgen Biopharma Latest Developments
Table 101. Cadila Healthcare Basic Information, Biosimilar Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 102. Cadila Healthcare Biosimilar Monoclonal Antibodies Product Offered
Table 103. Cadila Healthcare Biosimilar Monoclonal Antibodies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 104. Cadila Healthcare Main Business
Table 105. Cadila Healthcare Latest Developments
Table 106. Hisun Pharma Basic Information, Biosimilar Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 107. Hisun Pharma Biosimilar Monoclonal Antibodies Product Offered
Table 108. Hisun Pharma Biosimilar Monoclonal Antibodies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 109. Hisun Pharma Main Business
Table 110. Hisun Pharma Latest Developments
Table 111. Torrent Pharmaceuticals Basic Information, Biosimilar Monoclonal Antibodies Manufacturing Base, Sales Area and Its Competitors
Table 112. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Product Offered
Table 113. Torrent Pharmaceuticals Biosimilar Monoclonal Antibodies Sales (K Units), Revenue ($ Million), Price (USD/Unit) and Gross Margin (2019-2021E)
Table 114. Torrent Pharmaceuticals Main Business
Table 115. Torrent Pharmaceuticals Latest Developments
List of Figures
Figure 1. Picture of Biosimilar Monoclonal Antibodies
Figure 2. Biosimilar Monoclonal Antibodies Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Biosimilar Monoclonal Antibodies Sales Growth Rate 2016-2026 (K Units)
Figure 7. Global Biosimilar Monoclonal Antibodies Revenue Growth Rate 2016-2026 ($ Millions)
Figure 8. Biosimilar Monoclonal Antibodies Sales by Region (2021 & 2026) & ($ millions)
Figure 9. Product Picture of Infliximab
Figure 10. Product Picture of Rituximab
Figure 11. Product Picture of Trastuzumab
Figure 12. Product Picture of Adalimumab
Figure 13. Product Picture of Other
Figure 14. Global Biosimilar Monoclonal Antibodies Sales Market Share by Type in 2020
Figure 15. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Type (2016-2021)
Figure 16. Biosimilar Monoclonal Antibodies Consumed in Oncology
Figure 17. Global Biosimilar Monoclonal Antibodies Market: Oncology (2016-2021) & (K Units)
Figure 18. Biosimilar Monoclonal Antibodies Consumed in Autoimmune Disease
Figure 19. Global Biosimilar Monoclonal Antibodies Market: Autoimmune Disease (2016-2021) & (K Units)
Figure 20. Biosimilar Monoclonal Antibodies Consumed in Other
Figure 21. Global Biosimilar Monoclonal Antibodies Market: Other (2016-2021) & (K Units)
Figure 22. Global Biosimilar Monoclonal Antibodies Sales Market Share by Application (2016-2021)
Figure 23. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Application in 2020
Figure 24. Global Biosimilar Monoclonal Antibodies Revenue Market by Company in 2020 ($ Million)
Figure 25. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Company in 2020
Figure 26. Global Biosimilar Monoclonal Antibodies Sales Market Share by Regions (2016-2021)
Figure 27. Global Biosimilar Monoclonal Antibodies Revenue Market Share by Region in 2020
Figure 28. Americas Biosimilar Monoclonal Antibodies Sales 2016-2021 (K Units)
Figure 29. Americas Biosimilar Monoclonal Antibodies Revenue 2016-2021 ($ Millions)
Figure 30. APAC Biosimilar Monoclonal Antibodies Sales 2016-2021 (K Units)
Figure 31. APAC Biosimilar Monoclonal Antibodies Revenue 2016-2021 ($ Millions)
Figure 32. Europe Biosimilar Monoclonal Antibodies Sales 2016-2021 (K Units)
Figure 33. Europe Biosimilar Monoclonal Antibodies Revenue 2016-2021 ($ Millions)
Figure 34. Middle East & Africa Biosimilar Monoclonal Antibodies Sales 2016-2021 (K Units)
Figure 35. Middle East & Africa Biosimilar Monoclonal Antibodies Revenue 2016-2021 ($ Millions)
Figure 36. Americas Biosimilar Monoclonal Antibodies Sales Market Share by Country in 2020
Figure 37. Americas Biosimilar Monoclonal Antibodies Revenue Market Share by Country in 2020
Figure 38. Americas Biosimilar Monoclonal Antibodies Sales Market Share by Type in 2020
Figure 39. Americas Biosimilar Monoclonal Antibodies Sales Market Share by Application in 2020
Figure 40. United States Biosimilar Monoclonal Antibodies Revenue Growth 2016-2021 ($ Millions)
Figure 41. Canada Biosimilar Monoclonal Antibodies Revenue Growth 2016-2021 ($ Millions)
Figure 42. Mexico Biosimilar Monoclonal Antibodies Revenue Growth 2016-2021 ($ Millions)
Figure 43. Brazil Biosimilar Monoclonal Antibodies Revenue Growth 2016-2021 ($ Millions)
Figure 44. APAC Biosimilar Monoclonal Antibodies Sales Market Share by Region in 2020
Figure 45. APAC Biosimilar Monoclonal Antibodies Revenue Market Share by Regions in 2020
Figure 46. APAC Biosimilar Monoclonal Antibodies Sales Market Share by Type in 2020
Figure 47. APAC Biosimilar Monoclonal Antibodies Sales Market Share by Application in 2020
Figure 48. China Biosimilar Monoclonal Antibodies Revenue Growth 2016-2021 ($ Millions)
Figure 49. Japan Biosimilar Monoclonal Antibodies Revenue Growth 2016-2021 ($ Millions)
Figure 50. Korea Biosimilar Monoclonal Antibodies Revenue Growth 2016-2021 ($ Millions)
Figure 51. Southeast Asia Biosimilar Monoclonal Antibodies Revenue Growth 2016-2021 ($ Millions)
Figure 52. India Biosimilar Monoclonal Antibodies Revenue Growth 2016-2021 ($ Millions)
Figure 53. Australia Biosimilar Monoclonal Antibodies Revenue Growth 2016-2021 ($ Millions)
Figure 54. Europe Biosimilar Monoclonal Antibodies Sales Market Share by Country in 2020
Figure 55. Europe Biosimilar Monoclonal Antibodies Revenue Market Share by Country in 2020
Figure 56. Europe Biosimilar Monoclonal Antibodies Sales Market Share by Type in 2020
Figure 57. Europe Biosimilar Monoclonal Antibodies Sales Market Share by Application in 2020
Figure 58. Germany Biosimilar Monoclonal Antibodies Revenue Growth 2016-2021 ($ Millions)
Figure 59. France Biosimilar Monoclonal Antibodies Revenue Growth 2016-2021 ($ Millions)
Figure 60. UK Biosimilar Monoclonal Antibodies Revenue Growth 2016-2021 ($ Millions)
Figure 61. Italy Biosimilar Monoclonal Antibodies Revenue Growth 2016-2021 ($ Millions)
Figure 62. Russia Biosimilar Monoclonal Antibodies Revenue Growth 2016-2021 ($ Millions)
Figure 63. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Market Share by Country in 2020
Figure 64. Middle East & Africa Biosimilar Monoclonal Antibodies Revenue Market Share by Country in 2020
Figure 65. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Market Share by Type in 2020
Figure 66. Middle East & Africa Biosimilar Monoclonal Antibodies Sales Market Share by Application in 2020
Figure 67. Egypt Biosimilar Monoclonal Antibodies Revenue Growth 2016-2021 ($ Millions)
Figure 68. South Africa Biosimilar Monoclonal Antibodies Revenue Growth 2016-2021 ($ Millions)
Figure 69. Israel Biosimilar Monoclonal Antibodies Revenue Growth 2016-2021 ($ Millions)
Figure 70. Turkey Biosimilar Monoclonal Antibodies Revenue Growth 2016-2021 ($ Millions)
Figure 71. GCC Country Biosimilar Monoclonal Antibodies Revenue Growth 2016-2021 ($ Millions)
Figure 72. Channels of Distribution
Figure 73. Distributors Profiles

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analyzing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.

Please Choose License Type

USD $2900
USD $3900
USD $4900
COVID-19
Offer

WHY US?

  • Why Us In-depth database
    Our Report’s database covers almost all topics of all regions over the Globe..
  • Why Us Recognised publishing sources
    Tie ups with top publishers around the globe.
  • Why Us Customer Support
    Complete pre and post sales support.
  • Why Us Safe & Secure
    Complete secure payment process.